Skip to main content
NUFORMIX PLC logo

NUFORMIX PLC — Investor Relations & Filings

Ticker · NFX ISIN · GB00BYW79Y38 LEI · 2138003XG3H3I2J3BJ24 IL Professional, scientific and technical activities
Open in API
Filings indexed 279 across all filing types
Latest filing 2019-02-20 Major Shareholding Noti…
Country GB United Kingdom
Listing IL NFX

About NUFORMIX PLC

https://www.nuformix.com/

Nuformix PLC is a pharmaceutical development company focused on drug repurposing to address unmet medical needs, particularly in fibrosis and oncology. The company utilizes its expertise in cocrystal technology to unlock the therapeutic potential of approved drugs. This strategy involves creating new solid forms of existing medicines to improve their physical properties and performance, aiming to develop novel treatments with potentially accelerated development timelines.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly identified by the header 'RNS Number : 6682Q' and contains the standard format for 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership thresholds, which directly corresponds to the definition of Major Shareholding Notification. Although it is distributed via RNS (Regulatory News Service), the specific content dictates the classification should be MRQ (Major Shareholding Notification) rather than the general RNS fallback.
2019-02-20 English
Unaudited Half Year Results
Earnings Release Classification · 1% confidence The document explicitly states it contains 'Unaudited Half Year Results for the six months ended 30 September 2018'. It includes detailed financial statements like the Consolidated Income Statement and Statement of Financial Position comparing the current half-year period to the prior year's half-year and the last audited full year. This content structure is characteristic of a comprehensive financial report covering a period shorter than a full year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Although it is an announcement (RNS number present), the document text provided is extensive and contains the actual financial statements, making it the report itself, not just a publication announcement (RPA). H1 2018
2018-12-20 English
Reports Results from Novel IPF Pre-Clinical Trial
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '03 December 2018'. It announces specific scientific results ('Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme') and concludes with a disclosure regarding Market Abuse Regulation (MAR) and a footer stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure is characteristic of a general regulatory news service announcement, which falls under the 'Regulatory Filings' category (RNS) when it doesn't fit a more specific category like ER, CT, or DIV. While it contains scientific results, it is presented as a formal regulatory news release rather than a comprehensive financial report (10-K, IR) or a dedicated investor presentation (IP).
2018-12-03 English
Expansion of NXP001 Agreement & Milestone Payment
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated 27 November 2018. It announces an expansion of a licensing agreement and the receipt of a milestone payment, which are typical corporate updates. The text explicitly mentions that the information was provided by RNS, the news service of the London Stock Exchange, and that it is subject to Market Abuse Regulation (MAR) disclosure, indicating it is a regulatory announcement. Since it is a general corporate update that doesn't fit specific categories like Director's Dealing (DIRS), Dividend (DIV), or Earnings Release (ER), the most appropriate classification is the general regulatory announcement category.
2018-11-27 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is explicitly marked with an 'RNS Number' and contains a standard disclaimer stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a transaction by a Non-Executive Director (PDMR) involving the acquisition of company shares. This type of insider transaction disclosure is a specific regulatory filing. While 'Director's Dealing' (DIRS) is a strong candidate, the presence of the RNS header and the nature of the announcement as a general regulatory news service release strongly suggests classification under the broader regulatory announcement category, RNS, especially since DIRS often refers to the specific form filed with the regulator, whereas this is the public dissemination via the news service. However, given the highly specific definition for 'Director's Dealing' (DIRS) which covers 'Report of personal share transactions by company directors and executives (insider trades)', DIRS is the most precise fit for the *content* of the filing, even if it is distributed via RNS. I will prioritize the content type (Director's Dealing) over the distribution channel (RNS) when a specific content code exists. The document reports a PDMR transaction, which aligns perfectly with the DIRS definition.
2018-09-28 English
Additional New NXP002 Patent Filing
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' It announces a specific corporate event: 'Additional New NXP002 Patent Filing' and includes a Market Abuse Regulation (MAR) Disclosure, indicating it is a formal regulatory announcement. Since it is a specific announcement that doesn't fit the criteria for ER, CT, DIV, or DIRS, and it is not a full report (like 10-K or IR), the most appropriate classification is the general regulatory announcement category, RNS.
2018-09-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.